EP1143958A3 - Pharmaceutical composition and use of rnsaid for treating inflammation - Google Patents

Pharmaceutical composition and use of rnsaid for treating inflammation

Info

Publication number
EP1143958A3
EP1143958A3 EP99968626A EP99968626A EP1143958A3 EP 1143958 A3 EP1143958 A3 EP 1143958A3 EP 99968626 A EP99968626 A EP 99968626A EP 99968626 A EP99968626 A EP 99968626A EP 1143958 A3 EP1143958 A3 EP 1143958A3
Authority
EP
European Patent Office
Prior art keywords
cox
nsaid
action
mrna synthesis
rnsaid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP99968626A
Other languages
German (de)
French (fr)
Other versions
EP1143958B8 (en
EP1143958B1 (en
EP1143958A2 (en
Inventor
William J. Wechter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22517175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1143958(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Loma Linda University filed Critical Loma Linda University
Publication of EP1143958A2 publication Critical patent/EP1143958A2/en
Publication of EP1143958A3 publication Critical patent/EP1143958A3/en
Application granted granted Critical
Publication of EP1143958B1 publication Critical patent/EP1143958B1/en
Publication of EP1143958B8 publication Critical patent/EP1143958B8/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to the use of enantiomerically pure R-NSAIDs for the treatment of inflammation. Preferably, the R-NSAID used is R-flurbiprofen and is administered in a dose of at least 5 milligrams per kilogram of body weight per day. The anti-inflammatory action of R-NSAIDs is due to their ability to interfere with the biosynthesis of COX-2 by inhibiting COX-2 mRNA synthesis, rather than by just blocking the action of the enzyme itself. In order to effect the inhibition of COX-2 mRNA synthesis, the R-NSAID must be present at relatively high doses. Because the R-NSAID is selective in its action, that is, it does not inhibit either COX-1 mRNA synthesis or the COX-1 enzyme itself, it can be administered in the required high doses because the tissue protective effects of prostaglandins made through the COX-1 pathway are not interfered with.
EP99968626A 1998-09-03 1999-09-03 Pharmaceutical composition and use of rnsaid for treating inflammation Revoked EP1143958B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14639598A 1998-09-03 1998-09-03
US146395 1998-09-03
PCT/US1999/020261 WO2000013684A2 (en) 1998-09-03 1999-09-03 Pharmaceutical composition and method for treatment of inflammation

Publications (4)

Publication Number Publication Date
EP1143958A2 EP1143958A2 (en) 2001-10-17
EP1143958A3 true EP1143958A3 (en) 2002-08-21
EP1143958B1 EP1143958B1 (en) 2007-01-31
EP1143958B8 EP1143958B8 (en) 2007-05-23

Family

ID=22517175

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99968626A Revoked EP1143958B8 (en) 1998-09-03 1999-09-03 Pharmaceutical composition and use of rnsaid for treating inflammation

Country Status (13)

Country Link
US (1) US6472433B2 (en)
EP (1) EP1143958B8 (en)
JP (1) JP2002524415A (en)
CN (1) CN1391470A (en)
AT (1) ATE353010T1 (en)
AU (1) AU6026099A (en)
CA (1) CA2342628C (en)
CY (1) CY1106541T1 (en)
DE (1) DE69933049T2 (en)
DK (1) DK1143958T3 (en)
ES (1) ES2281981T3 (en)
PT (1) PT1143958E (en)
WO (1) WO2000013684A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
AU770803B2 (en) 1998-12-23 2004-03-04 Idea Ag Improved formulation for topical non-invasive application in vivo
DK1031347T3 (en) 1999-01-27 2002-07-08 Idea Ag Transnasal transport / immunization with highly customizable carriers
PT1031346E (en) 1999-01-27 2002-09-30 Idea Ag NOT INVASIVE VACCINATION THROUGH SKIN
DE19907895A1 (en) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Use of R-arylpropionic acids for the production of medicaments for the treatment of diseases in humans and animals which can be influenced therapeutically by inhibiting the activation of NF-kB
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
DE10047319A1 (en) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Use of R-arylpropionic acids for the production of medicaments for the treatment of diseases which can be therapeutically influenced by inhibiting the activation of the nuclear transcription factor AP-1
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
JP2007528857A (en) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド Pharmaceutical methods, dosing regimens and dosage forms for the treatment of Alzheimer's disease
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
EP3078374B1 (en) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US20150183737A1 (en) * 2012-07-20 2015-07-02 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN113712960B (en) * 2021-09-23 2023-04-07 南京医科大学 Application of R-ketorolac in prevention and treatment of aortic dissection and aortic aneurysm

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (en) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung MEDICINAL PRODUCTS AND THEIR PREPARATION AND THEIR USE IN THE CONTROL OF PAIN AND / OR DEFENSE AND / OR FEVER OF ANIMALS AND PEOPLE
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE4319438C1 (en) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Analgesic and/or antiinflammatory medicaments - contg. sepd enantiomers of ketoprofen
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
IT1298214B1 (en) * 1998-01-28 1999-12-20 Dompe Spa SALTS OF (R) 2- (3-BENZOYLFENYL) PROPIONIC ACID AND THEIR PHARMACEUTICAL COMPOSITIONS.

Also Published As

Publication number Publication date
PT1143958E (en) 2007-04-30
US6472433B2 (en) 2002-10-29
ES2281981T3 (en) 2007-10-01
EP1143958B8 (en) 2007-05-23
CA2342628A1 (en) 2000-03-16
ATE353010T1 (en) 2007-02-15
DE69933049D1 (en) 2006-10-12
US20010012849A1 (en) 2001-08-09
EP1143958B1 (en) 2007-01-31
WO2000013684A2 (en) 2000-03-16
CA2342628C (en) 2009-07-07
CY1106541T1 (en) 2012-01-25
DE69933049T2 (en) 2007-10-04
JP2002524415A (en) 2002-08-06
DK1143958T3 (en) 2007-04-10
WO2000013684A3 (en) 2002-05-30
EP1143958A2 (en) 2001-10-17
CN1391470A (en) 2003-01-15
AU6026099A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
EP1143958B8 (en) Pharmaceutical composition and use of rnsaid for treating inflammation
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
YU49026B (en) THE USE OF 17 ß -(N-TERT-BUTYLCARBAMOYIL)-4-AZA-5-ALPHA-ANDROST-1-ENE-3-ONE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ANDROGENIC ALOPECIA
ES2172654T3 (en) USE OF NSAID FOR THE TREATMENT OF SCALE CARCINOMAS OF THE ORAL OR OROPHARING CAVITY.
WO2000049937A3 (en) Trpm-2 antisense therapy
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
BR0113447A (en) Method of treating or preventing cancer in a human, and, pharmaceutical composition
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
IL166657A0 (en) Pharmaceutical compositions containing an agent effective to reduce the effective amount of clusterin
MXPA02002681A (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
PL330910A1 (en) Mode of administering inhibitors of h+, k+ - atpase
MXPA02011247A (en) Combination chemotherapy.
AU4830097A (en) Use of an extract of Cimicifuga
IL140716A0 (en) Use of inhibitors of protein kinase c epsilon to treat pain
GEP20043157B (en) Medicament Against Migraine Recurrence
GEP20043231B (en) Resorcinol Composition
ID26965A (en) MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS
AU6846996A (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
US20040023937A1 (en) Anti-cancer formulation
CA2499620A1 (en) External preparation containing acetylsalicylic acid for inhibiting keloid formation
WO2001045740A3 (en) Compositions and methods for treatment of breast cancer
MY127741A (en) Wash-off vitamin e compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010320

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT

XX Miscellaneous (additional remarks)

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

17Q First examination report despatched

Effective date: 20020221

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

XX Miscellaneous (additional remarks)

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69933049

Country of ref document: DE

Date of ref document: 20061012

Kind code of ref document: P

PUAC Information related to the publication of a b1 document modified or deleted

Free format text: ORIGINAL CODE: 0009299EPPU

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG

DB1 Publication of patent cancelled
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT

XX Miscellaneous (additional remarks)

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

NLXE Nl: other communications concerning ep-patents (part 3 heading xe)

Free format text: PAT. BUL. 11/2006: PATENTNUMBER 1143958 SHOULD BE DELETED (SEE EUROPEAN PATENT BULLETIN 20061206/49)

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: DIE ERTEILUNG VOM 30.08.2006 WURDE VOM EPA WIDERRUFEN

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070327

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070401221

Country of ref document: GR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2281981

Country of ref document: ES

Kind code of ref document: T3

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: PAZ ARZNEIMITTEL- ENTWICKLUNGSGESELLSCHAFT MBH

Effective date: 20071030

Opponent name: NITEC PHARMA AG

Effective date: 20071026

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

NLR1 Nl: opposition has been filed with the epo

Opponent name: PAZ ARZNEIMITTEL- ENTWICKLUNGSGESELLSCHAFT MBH

Opponent name: NITEC PHARMA AG

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: LOMA LINDA UNIVERSITY MEDICAL CENTER

Free format text: LOMA LINDA UNIVERSITY MEDICAL CENTER#ROOM LLUMC-A505, 11234 ANDERSON STREET#LOMA LINDA, CALIFORNIA 92354 (US) -TRANSFER TO- LOMA LINDA UNIVERSITY MEDICAL CENTER#ROOM LLUMC-A505, 11234 ANDERSON STREET#LOMA LINDA, CALIFORNIA 92354 (US)

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20100827

Year of fee payment: 12

Ref country code: IE

Payment date: 20100910

Year of fee payment: 12

Ref country code: CH

Payment date: 20100914

Year of fee payment: 12

R26 Opposition filed (corrected)

Opponent name: PAZ ARZNEIMITTEL- ENTWICKLUNGSGESELLSCHAFT MBH

Effective date: 20071030

Opponent name: NITEC PHARMA AG

Effective date: 20071026

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20100913

Year of fee payment: 12

Ref country code: IT

Payment date: 20100916

Year of fee payment: 12

Ref country code: FR

Payment date: 20100921

Year of fee payment: 12

Ref country code: AT

Payment date: 20100910

Year of fee payment: 12

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20100817

Year of fee payment: 12

Ref country code: GB

Payment date: 20100901

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

27W Patent revoked

Effective date: 20101124

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20101124

REG Reference to a national code

Ref country code: PT

Ref legal event code: MP4A

Effective date: 20110112

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20100827

Year of fee payment: 12

Ref country code: DK

Payment date: 20100910

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20070131

Ref country code: CH

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20070131

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20101014

Year of fee payment: 12

Ref country code: DE

Payment date: 20100901

Year of fee payment: 12

Ref country code: BE

Payment date: 20100915

Year of fee payment: 12

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20101018

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20110912

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20110922

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20110822

Year of fee payment: 13